Why Am I So Hungry on Retatrutide?

Retatrutide is an investigational triple receptor agonist with no UK marketing authorisation, accessible only within authorised clinical trials. Some trial participants report unexpected or fluctuating hunger, which can be confusing given that the medicine is designed to reduce appetite. This article explains the pharmacology behind retatrutide's appetite-related effects, what Phase 2 trial data reported about hunger, and what other factors may contribute to increased appetite during a trial. If you are a participant experiencing persistent hunger, the appropriate first step is to raise this with your trial clinical team.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide has no UK marketing authorisation and cannot be prescribed or supplied outside an authorised clinical trial. The MHRA has not evaluated it for safety, quality or efficacy in routine clinical use.

Retatrutide holds no marketing authorisation in the UK or anywhere else, meaning it is not a licensed medicine and can only be accessed within an authorised clinical trial. It is an investigational compound developed by Eli Lilly that acts simultaneously on three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor.^[5][6] This triple agonist mechanism distinguishes it pharmacologically from currently licensed treatments, though no authorised head-to-head comparisons exist.

Because retatrutide has no UK marketing authorisation, the Medicines and Healthcare products Regulatory Agency (MHRA) has not evaluated it for safety, quality or efficacy outside the trial setting. It cannot be advertised, and can be prescribed or supplied only within an authorised clinical trial. If you encounter any product sold online under this name, it is not a licensed medicine and may be falsified or unsafe.

For people interested in weight management support now, licensed treatments exist and can be discussed with a GP. No timeline can be given for any potential UK authorisation of retatrutide, and no date should be anticipated.

Why does hunger change when taking retatrutide?

During dose escalation, retatrutide's appetite-suppressing effects may not yet be fully established, meaning hunger signals can remain relatively unchanged or fluctuate. Any such experience should be discussed with the trial clinical team.

Retatrutide's triple receptor activity is designed to reduce appetite, but individual responses to investigational medicines vary considerably. The GLP-1 component slows gastric emptying and acts on appetite-regulating centres in the brain, promoting a sense of fullness.^[10][11] The GIP component modulates insulin secretion and may also influence energy balance.^[10][13] The glucagon receptor component increases energy expenditure and affects glucose metabolism.^[15][16] These are mechanistic considerations based on the known pharmacology of the three receptor pathways; they do not guarantee any particular experience for an individual participant.

During dose escalation, which is a gradual increase in the injected amount over several weeks, the appetite-suppressing effects may not yet be fully established. This is consistent with the pharmacology of incretin-based therapies more broadly, where appetite suppression tends to increase with dose. During this transitional period, hunger signals may remain relatively unchanged for some individuals.

Additionally, if caloric intake has been reduced in anticipation of appetite suppression, the body's homeostatic hunger mechanisms may respond by increasing appetite-stimulating hormones such as ghrelin. Whether glucagon receptor agonism at clinical doses contributes meaningfully to hunger sensations in humans remains a theoretical consideration rather than an established finding. Any experience of increased or fluctuating hunger during a retatrutide trial should be discussed with the trial clinical team.

What did clinical trials report about appetite and hunger levels?

Phase 2 trial data published in 2023 reported appetite reduction across treatment groups, particularly at higher doses, but published averages do not reflect every participant's individual experience.

Phase 2 trial data published in the New England Journal of Medicine in 2023 reported that participants receiving retatrutide experienced reductions in body weight over 48 weeks, with findings suggesting appetite suppression contributed to these outcomes.^[5][6] The TRIUMPH and TRANSCEND trial programmes represent the Phase 3 investigation of retatrutide across populations including people with obesity and those with type 2 diabetes, and results from these studies are informing the broader evidence base.^[7][8]

Within the Phase 2 trial, appetite reduction was reported across the treatment groups, particularly at higher dose levels, though the published data do not allow precise characterisation of how many participants experienced increased or fluctuating hunger. Trial populations are carefully selected and monitored, and reported averages do not reflect every participant's experience. Some individuals in trials of GLP-1 class medicines, including those with additional receptor targets, have described variable appetite responses, particularly during the early weeks of treatment or following dose adjustments.

It is important to understand that trial findings describe outcomes in specific, controlled populations over defined durations. They do not predict what any individual would experience. If you are a participant in a retatrutide trial and are noticing increased hunger, this should be reported directly to your trial clinical team as part of the study protocol.

Could something else be causing your increased hunger?

Increased hunger during a trial may stem from compensatory ghrelin rises due to dietary restriction, poor sleep, stress, hypoglycaemia or other medications, rather than the investigational medicine itself.

Increased hunger during participation in a clinical trial may not be directly caused by the investigational medicine itself, and several other factors are worth considering. Dietary changes made in anticipation of appetite suppression, such as reducing portion sizes or skipping meals, can trigger compensatory hunger responses driven by the body's energy-sensing systems. If caloric intake drops significantly, ghrelin (the primary hunger-stimulating hormone) tends to rise, which can reduce the apparent appetite-suppressing effect of any treatment.^[17][18]

Hypoglycaemia (low blood glucose) can also cause hunger, and trial participants who notice symptoms such as shakiness, sweating, dizziness or sudden intense hunger should report these to the trial team promptly.

Sleep quality is another important factor. Poor or disrupted sleep is well established as a driver of increased appetite, particularly for energy-dense foods, through its effects on leptin and ghrelin levels. Stress and anxiety, which may themselves be heightened during participation in a clinical trial, can also stimulate appetite through cortisol-mediated pathways.^[21][22]

Underlying health conditions should also be considered. Thyroid dysfunction, insulin resistance, and certain medications (including corticosteroids and some antidepressants) can all increase hunger independently of any trial medicine.^[26][27] If you are a trial participant experiencing persistent or worsening hunger, it is appropriate to raise this with your trial team, who can assess whether it relates to the study medicine, the dose level, or another cause entirely. Do not adjust your diet or other medications without guidance from the trial clinical team.

What side effects and safety concerns have been observed in trials?

The most commonly reported side effects in Phase 2 trials were gastrointestinal, including nausea, vomiting and diarrhoea, generally more frequent at higher doses. Severe abdominal pain requires immediate emergency attention.

In the Phase 2 trial of retatrutide, the most commonly reported side effects were gastrointestinal in nature, including nausea, vomiting, diarrhoea and constipation. These were generally more frequent at higher doses and during dose escalation, and they tended to decrease over time, consistent with the pattern seen with other medicines in this class. Injection site reactions were also reported.

As with other medicines acting on the GLP-1 receptor, acute pancreatitis has been reported in the GLP-1 class more broadly, and participants in retatrutide trials are monitored for this. If you develop severe, persistent abdominal pain that may radiate to the back, with or without vomiting, seek urgent medical attention immediately by calling 999 or attending A&E. Tell emergency clinicians that you are enrolled in a clinical trial and show your trial identification card or participant information sheet if you have one.

Because retatrutide also acts on the glucagon receptor, there are theoretical considerations around effects on blood glucose, heart rate and blood pressure that are being evaluated within the trial programme. Participants with pre-existing diabetic eye disease should be aware that rapid improvements in blood glucose control have been associated with transient worsening of pre-existing pre-proliferative or proliferative diabetic retinopathy in trials of related medicines; this is a recognised phenomenon in people with existing diabetic eye disease and is monitored within trials.^[23][24]

Retatrutide trials exclude participants who are pregnant, breastfeeding or planning pregnancy, and appropriate contraception is required for participation. These exclusions reflect the absence of safety data in these populations for an investigational medicine.

Do not stop, skip or change your trial medication or dose without speaking to your trial team first. If you are a trial participant and experience any concerning symptoms, contact your trial team promptly. For urgent medical concerns, call 999 or attend A&E. For non-emergency advice, NHS 111 is available. Suspected side effects within a clinical trial should be reported to the trial team under the study protocol; they can also be reported to the MHRA via the Yellow Card scheme at yellowcard.^[28][29]mhra.gov.uk.

Frequently Asked Questions